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ABSTRACT
Objectives Review of efficacy and safety of Janus kinase
(JAK) inhibition in immune-mediated inflammatory diseases
(IMIDs).
Methods A systematic literature research (SLR) of all
publications on JAK inhibitors (JAKi) treatment published
until March 2019 using MEDLINE, EMBASE and the
Cochrane Library. Efficacy and safety were assessed in
randomised controlled trials (RCTs), integrating long-term
extension periods additionally for safety evaluation.
Results 3454 abstracts were screened with 85 included in
the final analysis (efficacy and RCT safety: n=72; safety
only: n=13). Efficacy of RCTs investigating tofacitinib (TOFA,
n=27), baricitinib (BARI, n=9), upadacitinib (UPA, n=14),
filgotinib (FILGO, n=7), decernotinib (DEC, n=3) and
peficitinib (PEF, n=7) was evaluated. Six head-to-head trials
comparing JAKi with tumour necrosis factor inhibitors (TNFi)
were included. Efficacy of JAKi was shown in rheumatoid
arthritis (RA) for all agents, psoriatic arthritis (TOFA, FILGO),
ankylosing spondylitis (TOFA, FILGO), systemic lupus
erythematosus (BARI), chronic plaque psoriasis (TOFA,
BARI, PEF), ulcerative colitis (TOFA, UPA), Crohn’s disease
(UPA, FILGO) and atopic dermatitis (TOFA, BARI, UPA). Safety
analysis of 72 RCTs, one cohort study and 12 articles on
long-term extension studies showed increased risks for
infections, especially herpes zoster, serious infections and
numerically higher rates of venous thromboembolic events.
No increased malignancy rates or major adverse cardiac
events were observed.
Conclusion JAKi provide good efficacy compared to
placebo (and to TNFi in RA and Pso) across various IMIDs
with an acceptable safety profile. This SLR informed the task
force on points to consider for the treatment of IMIDs with
JAKi with the available evidence.
INTRODUCTION
The first randomised controlled trial
(RCT) investigating the inhibition of Janus
kinases (JAK) via the JAK-1/2 selective
agent ruxolitinib/INCB018424 (RUXO) in
patients with an immune-mediated
inflammatory disease (IMID), namely rheu-
matoid arthritis (RA), was completed in
2008; however, this study has not been pub-
lished until today (ClinicalTrials.gov identi-
fier: NCT00550043). Since then, numerous
trials on JAK inhibitors (JAKi) have
been conducted in various IMIDs across
many disciplines, including rheumatology,
dermatology and gastroenterology.1–14
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What is already known about this subject?
► Numerous randomised controlled trials investigating the
efficacy and safety of Janus kinase inhibitors in immune-
mediated inflammatory diseases have been conducted.
What does this study add?
► JAKi were effective in reducing signs and symptoms
in rheumatic diseases (rheumatoid and psoriatic
arthritis, ankylosing spondylitis and systemic lupus
erythematosus) as well as inflammatory bowel
disease (ulcerative colitis and Crohn’s disease) and
immune-mediated dermatological diseases like
chronic plaque psoriasis and atopic dermatitis.
► Janus kinase inhibitors showed an acceptable safety
profile in the investigated populations, with an
increased risk for infections (including serious
infections and herpes zoster). Rare events were
difficult to assess for some agents due to the
limited amount of patient-exposure-years and only
few registry data. However, numerically higher rates
of venous thromboembolic events were seen in JAKi-
treated patients in some studies.
How might this impact on clinical practice?
► This SLR was performed to inform the task force on
‘Points to consider for the treatment of immune-
mediated inflammatory diseases with Janus kinase
inhibitors’with the evidence published until March 2019.
Autoimmunity
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In 2012, tofacitinib (TOFA), a JAK-1/2/3 inhibitor, was
the first agent to be approved for an IMID, namely RA,
but subsequently also for treating paients with psoriatic
arthritis (PsA) and ulcerative colitis (UC). While JAK
inhibition via baricitinib (BARI; JAK-1/2), upadacitinib
(UPA; JAK-1/2) and filgotinib (FILGO; JAK-1) also
showed good efficacy in different indications, questions
on how JAK selectivity influences clinical efficacy as well as
the safety profile of all these agents arose and are still
insufficiently answered, continue to be issues for debate
and future research.15
To guide the practicing clinician on how (not when) to
use JAKi in clinical practice, the consensus meeting on
‘Points to consider for the treatment of immune-
mediated inflammatory diseases with Janus kinase inhibi-
tors’was conducted in 2019. Participants of the consensus
task force were informed by this systematic literature
research (SLR) on the efficacy and safety of all trials on
JAKi conducted in IMIDs.
METHODS
A review protocol for this SLR was developed by the
steering group in accordance with the EULAR standar-
dised operating procedures for recommendations.16
The systematic literature search was conducted by
a database expert (LF) in EMBASE, Medline and the
Cochrane Library. The search included all studies pub-
lished from the earliest date indexed until 12 March 2019
(last date searched). Further, the conference abstract
archives of the EULAR Annual Meeting and American
college of rheumatology (ACR, until 2018) were hand-
searched. All search terms used are shown in the online
supplemental appendix (Section 1.1.1–1.1.3). Data
extraction was done by one researcher (AK) in duplicates.
The eligibility criteria for inclusion were defined as
studies in adult patients (≥18 years) treated with JAKi
with diagnosed active autoimmune disease, that is, RA,
PsA, AS, systemic lupus erythematosus (SLE), Crohn’s
disease (CD), UC, psoriasis (PsO), atopic dermatitis
(AD) or alopecia areata (AA) and alopecia universalis.
Patient populations were defined for each disease sepa-
rately, based on treatment history such as an insufficient
response (IR) to certain previous systemic therapies. Data
of full articles could be included also if published after
the last date of the database search, provided at least one
abstract of the respective trial had been published within
the SLR’s time frame.
For efficacy evaluation, only randomised, controlled,
double-blind trials on systemic or topical JAKi including
BARI, decernotinib (DEC), FILGO, peficitinib (PEF),
RUXO, TOFA and UPA treatment were considered.
A detailed list of patient populations, interventions, con-
trols and outcomes is shown in the online supplemental
appendix (section 1.4.1.1–1.4.1.4). For safety evaluation,
RCTs were evaluated for signals of adverse events (AEs).
In addition, cross-sectional, cohort and case–control stu-
dies were eligible.
Research questions developed by the steering group are
shown in sections 1.4.2 (for efficacy) and 1.4.3 (for safety)
in the online supplemental appendix.
Safety outcomes of interest were infections, malignan-
cies, venous thromboembolic events (VTE), haematolo-
gical abnormalities (anaemia, leucopenia, neutropenia,
lymphopenia), MACE and laboratory abnormalities
(hepatic, cholesterol, creatine kinase).
As decided by the steering group, due to expected
heterogeneity of the populations investigated, no pooling
of efficacy or safety results by meta-analysis was
conducted.
Risk of bias (RoB) was assessed using the Cochrane
Collaboration’s RoB tool for RCTs, assigning each study
as having low, unclear or high RoB.17
RESULTS
A total of 3454 studies were assessed in the title and
abstract screening with 262 selected for full article review;
85 publications were finally evaluated in detail. Figure 1
shows the study flow chart with a detailed description of
the selection process. Reports on efficacy selected for
inclusion are shown in table 1 (detailed results of
included articles are shown in online supplemental
appendix tables S2.1.1–2.1.9).
Most of the articles showed a low overall RoB, with few
articles considered to be of unclear risk due to insuffi-
cient reporting on random sequence generation and
allocation procedures. One study was considered to
have a high RoB due to dosage unblinding of participants
and investigators.18 Details are shown in the online sup
plemental appendix (tables S2.2.1–S2.2.9).
Figure 2 visualises efficacy results of different JAKi by
disease, based on the achievement of primary clinical end
points. Baseline characteristics (tables S2.3.1–S2.3.9) and
detailed efficacy results (tables S3.1–S3.9) are shown in
the online supplemental appendix.
Besides safety data of clinical trials investigated for effi-
cacy, 13 additional reports on safety were included
(details of selected articles are shown in online supple
mental appendix tables S4.1.1–S4.1.8; safety outcomes
are shown in online supplemental appendix tables S4.2.
1–S4.2.8 and S4.3.1–S4.3.8).
Rheumatoid arthritis
In total, 39 primary reports of clinical trials on JAKi in
patients with RA were included (low RoB: n=28; unclear
RoB: n=9; conference abstracts: n=3; for details on study
characteristics, RoB analyses, baseline characteristics and
efficacy outcomes, see online supplemental appendix
tables S2.1.1, S2.2.1, S2.3.1 and S3.1).
TOFA was effective in reducing signs and symptoms of
RA as well as inhibition of radiographic damage progres-
sion. These studies were performed in methotrexate
(MTX)-naïve patients,19 patients with IR to MTX,20 21 or
conventional synthetic disease-modifying drugs
(csDMARDs)1 22–27 or to tumour necrosis factor alpha
RMD Open
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inhibitors (TNFi) and other biological (b)DMARDs1 28 29;
structural outcomes were only studied in MTX-naïve and
MTX-IR patients. In MTX-IR patients, van Vollenhoven
et al showed numerically similar response rates of TOFA
and adalimumab (ADA), which was used as an active
comparator but not powered for non-inferiority in the
ORAL Standard trial.30 ORAL-Strategy, a head-to-head
trial comparing TOFA 5 mg twotimes per day monother-
apy and TOFA 5 mg two times per day plus MTX with
ADA 40 mg every other week (EOW) plus MTX, proved
non-inferiority between the combination therapy arm but
not for the TOFA monotherapy arm compared with the
two combination arms (table 2).31
Studies on BARI also revealed the efficacy of BARI 2mg
and 4 mg once daily (OD) in csDMARD-naïve,36 MTX
and csDMARD-IR,37–40 and patients previously not
responding to bDMARDs, compared with placebo.2 In
RA-BEAM, BARI 4 mg was statistically superior clinically
over placebo and ADA 40 mg EOW in MTX-IR patients
(table 2).32 In a randomised tapering substudy of RA-
BEYOND, Takeuchi et al showed that patients on BARI
4 mg OD who had achieved low disease activity according
to the Clinical Disease Activity Index (CDAI, ≤10) and
were subsequently randomised to reduce the BARI dose
from 4 mg to 2 mg OD mostly maintained their disease
state, although less so than continuing full dose
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Figure 1 PRISMA flow chart for studies on JAKi efficacy and/or safety in inflammatory immune disease, published until
March 2019. JAKi, Janus kinase inhibitors; PRISMA, PreferredReporting Items for Systematic Reviews and Meta-Analyses.
Autoimmunity
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(CDAI≤10 at week 48: continued BARI 4mg vs tapering to
BARI 2 mg: 80% vs 67%; patients achieving CDAI≤2.8,
that is, remission: BARI 4 mg vs 2 mg: 40% vs 33%); there
was a numerically lower rate of non-serious infections in
the tapering arm.41 42
UPA was investigated in eight trials, also provided
good efficacy results across various patient populations
with RA (MTX-naïve, MTX-IR, csDMARD-IR, TNF-IR
and bDMARD-IR) compared to placebo and both as
monotherapy and when combined with MTX.3 37 43–50
A head-to-head comparison of UPA+MTX with ADA
40 mg EOW + MTX demonstrated superiority
(clinically and functionally) of UPA+MTX versus ADA
+MTX and versuss placebo + MTX (table 2).33 34 In
SELECT-MONOTHERAPY, MTX-IR patients were either
randomised to blinded UPA 15 mg OD, UPA 30 mg OD
or continued MTX for 14 weeks. UPA showed statisti-
cally superior responses in clinical and functional out-
comes, compared to continued MTX (ACR20 at week
14: 68%, 71% and 41% for UPA 15 mg OD, 30 mg OD
and continued MTX, respectively).44 45
Treatment with FILGO in MTX-IR patients showed
superiority compared to placebo in four phase II
RCTs.4 51 52 FILGO monotherapy (DARWIN 2) was
















39 13 6 8 4 3 5 0
Psoriatic arthritis 3 2 0 0 1 0 0 0
Ankylosing
spondylitis
2 1 0 0 1 0 0 0
Systemic lupus
erythematosus
2 0 1 0 0 0 0 Solcitinib (1)
Chronic plaque
psoriasis
10 6 1 0 0 0 1 BMS-986 165 (1)
Itacitinib (1)
Ulcerative colitis 6 2 0 3 0 0 1 0
Crohn’s disease 5 2 0 2 1 0 0 0
Alopecia areata/
universalis
1 0 0 0 0 0 0 PF-06651600 (1)
Atopic dermatitis 4 1 1 1 0 0 0 JTE-052 (1)
Total 72 27 9 14 7 3 7 5
JAK, Janus kinase.
Disease





















Statistically superior compared to placebo
No significant difference compared to placebo
Not available
Figure 2 Efficacy of Janus kinase inhibiting agents across immune-mediated diseases (based on available data at end of
March 2019). JAK, Janus kinase.
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Table 2 Trials investigating Janus kinase inhibitors and tumour necrosis factor alpha inhibitors
Study Population
Risk of
bias Treatment n Primary end point P value
% of patients achieving primary
end point
Rheumatoid arthritis
van Vollenhoven 2012 (ORAL
Standard)30
MTX-IR Low PLC+MTX (Combination group) 106 % ACR20 (week 24) Reference 28
TOFA 5 mg two times per day
+MTX
204 <0.001 52
TOFA 10 mg two times per day
+MTX
201 <0.001 53
ADA 40 mg EOW+MTX 204 <0.001 47
Fleischmann 2017 (ORAL
Strategy)31
MTX-IR Low TOFA 5mg two times per day+PLC 384 Non-inferiority:
% ACR50 (week 24)
NI not met
−8% (98.34% CI −16
to 1)
65
TOFA 5 mg two times per day
+MTX
376 NI met
2% (98.34% CI −6 to
11)
73
ADA 40 mg Q2W+MTX 386 Reference 71
Taylor 2017 (RA-BEAM)32 MTX-IR Low PLC+MTX 488 Superiority:
% ACR20 (week 12)
– 40
BARI 4 mg+MTX 487 0.01 70
ADA 40 mg EOW+MTX 330 Reference 61
Fleischmann 2018 (SELECT-
COMPARE)33 34
MTX-IR Low PLC+MTX 651 Superiority:
% ACR50 (week 12)
– 15
UPA 15 mg OD+MTX 651 <0.001 45
ADA 40 mg EOW+MTX 327 Reference 29
Psoriatic arthritis




TOFA 5 mg two times per day
±csDMARD
107 <0.01; 0.006 50; −0.35
TOFA 10 mg two times per day
±csDMARD
104 <0.001; <0.001 61; −0.4
ADA 40 mg EOW±csDMARD 106 NR 52; −0.38
Chronic plaque psoriasis





Low Placebo 107 Non-inferiority:





TOFA 5 mg two times per day 329 NI not met
<0.001/<0.001
40
TOFA 10 mg two times per day 330 NI met
0.20/0.60
64
ETA 50 mg twice weekly 335 Reference 59
ACR, American College of Rheumatology; ADA, adalimumab; BARI, baricitinib; csDMARD, conventional synthetic disease-modifying antirheumatic drug; EOW, every other week; ETA, etanercept;
ΔHAQ, changes frombaseline in Health AssessmentQuestionnaire-Disability Index; IR, insufficient responder;MTX,methotrexate; NI, non-inferiority; PASI, Psoriasis Area and Severity Index; PGA,




















































superior to placebo after MTX washout (ACR20 at
week 12: 67% vs 66% vs 73% vs 29% for FILGO
50 mg OD, 100 mg OD, 200 mg OD and placebo,
respectively).4 51 52 FILGO in combination with MTX
also showed superiority over placebo + MTX in DAR-
WIN 1 (ACR20 at week 12: 56% vs 64% vs 69% vs 57%
vs 60% vs 79% vs 44% for FILGO 50 mg OD, 100 mg
OD, 200 mg OD, 25 mg two times per day, 50 mg two
times per day, 100 mg two times per day and placebo,
respectively).4 DEC (JAK-3 selective) showed superior-
ity over placebo in three trials; however, no clear
dose–response relationship exists in ACR
responses.53–55 PEF, another pan-JAKi (JAK 1–3), was
investigated in two global trials, where it failed to
reveal significant efficacy (Genovese 2017: ACR20 at
week 12: 22.0% vs 36.8% vs 56.3% vs 29.3%; Kivitz
2017: 43.9% vs 61.5% vs 46.4% vs 57.7% vs 44.4%
for PEF 25 mg OD, 50 mg OD, 100 mg OD, 150 mg
OD and placebo, respectively). But in several Japanese
RA study populations (MTX-naïve, MTX-IR,
csDMARD-IR), it showed significant improvement of
signs and symptoms and physical function compared
to placebo.56–62
PsA, ankylosing spondylitis and SLE
In PsA, three trials (all with low RoB) were published (for
details, see online supplemental appendix tables S2.1.2,
S2.2.2, S2.3.2 and S3.2). TOFA was investigated in two
phase III trials, showing efficacy not only regarding signs
and symptoms of arthritis but also physical function, skin
disease, dactylitis and enthesitis.5 63 Similar results across
many outcomes (although not formally tested) in
patients with csDMARD-IR PsA were observed with
TOFA compared to ADA 40 mg EOW (table 2).5 Treat-
ment with FILGO 200 mg OD in EQUATOR resulted in
significant improvements compared to placebo regard-
ing signs and symptoms of arthritis, PsO and enthesitis.64
In ankylosing spondylitis, two trials in patients with IR
to non-steroidal anti-inflammatory drugs were available
for analysis, one on TOFA and one on FILGO (for details,
see online supplemental appendix tables S2.1.3, S2.2.3,
S2.3.3 and S3.3).6 65 In a phase II trial (unclear RoB),
TOFA significantly improved clinical outcomes of spinal
mobility, pain and function as well as inflammatory
changes by MRI, with a clear dose–response.6 In phase
II trial (low RoB), FILGO improved disease activity sig-
nificantly more than placebo across various outcome
measures.65
Only limited data on JAKi in SLE were published (two
trials, one with high RoB, one with low RoB; for details,
see online supplemental appendix tables S2.1.4, S2.2.4,
S2.3.4 and S3.4).7 18 In a phase II study, Wallace et al
investigated BARI in patients with SLE and active skin or
joint disease. Significantly more patients achieved
a SLEDAI-2 K resolution of arthritis or rash at week 24
with BARI 4 mg OD (but not BARI 2 mg OD) compared
to placebo treatment.7
Chronic plaque PsO, AD and alopecia
Ten trials on patients suffering from chronic plaque
PsO were included in this SLR (for details, see online
supplemental appendix tables S2.1.5, S2.2.5, S2.3.5 and
S3.5), eight with low, one with unclear and one with
high RoB, respectively. TOFA showed significant
improvements in skin disease compared to placebo in
patients who were candidates for systemic therapy or
phototherapy.8 35 66 67 Bachelez et al could demonstrate
non-inferiority of TOFA 10 mg two times per day com-
pared with etanercept 50 mg twice weekly in achieving
a Psoriasis Area and Severity Index (PASI) 75%
response as well as clear or almost clear skin (as evalu-
ated by the physician global assessment, PGA) at week
12 (table 2).35 In a withdrawal and retreatment trial,
patients with treatment response to TOFA 5 mg or
10 mg two times per day at week 24 were re-
randomised to placebo or their previous TOFA dose.
Moreover, 23.3% and 26.1% of the patients withdrawn
from TOFA 5 mg and 10 mg two times per day, respec-
tively, could maintain their PASI75% response (com-
pared to 56.2% and 62.3% with ongoing TOFA 5 mg
or 10 mg two times per day) after 16 weeks. Following
16 weeks of retreatment, 36.8% and 61% of the patients
who relapsed after treatment withdrawal, could again
achieve a PASI 75% response (compared with 63%
and 73.8% of the patients continuously treated with
TOFA 5 mg or 10 mg two times per day,
respectively).68 A dose-finding study investigating BARI
showed BARI 8 mg OD as well as 10 mg OD (but
neither 2 mg OD nor 4 mg OD) to be significantly
better than placebo in achieving the primary end
point (PASI75% at week 12).69 A JAK-1 selective JAKi,
itacinib (INCB039110), showed promising results in
a 28-day proof-of-concept PsO trial.70 BMS-986165, con-
sidered as selective TYK2 inhibitor, showed better clear-
ing of PsO than placebo at week 12.71
Topical TOFA showed greater improvements in pruri-
tus and eczema area and severity compared to vehicle
treatment in AD.72 Another topical pan-JAKi (JTE-052)
showed rapid and significant AD improvements over vehi-
cle treatment, with numerically similar results to open-
label topical tacrolimus, but potential unblinding during
the study (high RoB).73
Further, systemic treatment with BARI showed promis-
ing results in improving signs, symptoms and patient-
reported outcomes of AD.74 Dose-dependent responses
to UPA with significant differences compared to placebo
were demonstrated in a phase II study in patients with
moderate to severe AD (% change from baseline in
Eczema Area and Severity Index at week 16: 39% vs 62%
vs 74% vs 23% for UPA 7.5 mg OD, 15 mg OD, 30 mg OD
and placebo, respectively).9 10
Selective inhibition of JAK-3 via PF-06651600 and
TYK2/JAK1 via PF-06700841 showed statistically superior
results compared to placebo in patients with AA regard-
ing ≥50% improvement from baseline in severity of
RMD Open
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alopecia tool at 24 weeks (conference abstract, no RoB
analysis conducted).75
Inflammatory bowel disease
In total, eleven reports on eight trials in inflammatory
bowel disease were included, describing four trials on UC
(all with low RoB) and four on CD (3 low RoB, 1 unclear
RoB; for details, see online supplemental appendix tables
S2.1.7, S2.1.8, S2.2.7, S2.2.8, S2.3.7, S2.3.8, S3.7 and S3.
8).11–14 76–82
TOFA 10 mg two times per day was effective in UC as
induction therapy compared to placebo in UC, with
16.6% vs 8.2% achieving remission (defined as total
Mayo score ≤2, with no subscore >1 and a rectal bleeding
subscore of 0) at week 8. Patients with clinical response
were subsequently randomised to receive TOFA 10 mg
two times per day, TOFA 5 mg two times per day or
placebo with TOFA being significantly more effective
than placebo therapy after 52 weeks (34.3% vs 40.6% vs
11.1% for TOFA 5mg two times per day, TOFA 10mg two
times per day and placebo, respectively).76 Induction
therapy in patients with moderate to severe UC with
UPA was investigated in a phase II trial, being more
effective than placebo in inducing remission (0% vs
8.5% vs 14.3% vs 13.5% vs 19.6% for placebo, UPA
7.5 mg, 15 mg 30 mg or 45 mg OD) at week 8.77 78 In
a phase IIb study on PEF as induction therapy in UC, the
primary end point, establishment of a dose–response
relationship was not met. Only PEF 150 mg showed
a significant difference (nominal p<0.05) in inducing
remission at week 8 compared to placebo (7% vs 15.9%
vs 15.9% vs 27.3% vs 15.9% for placebo, 25 mgOD, 75 mg
OD, 150 mg OD or 75 mg two times per day).79
TOFA was not effective in treating patients with active
CD and insufficient response to glucocorticoids and
immunomodulatory agents (including TNFi), neither
for induction nor maintenance therapy in three phase II
trials.80 81 A phase II dose-finding study on UPA showed
clinical as well as endoscopic improvement in moderate-
to-severe CD (clinical/endoscopic remission at week 16:
11%/0% vs 13%/10% vs 27%/8% vs 11%/8% vs vs 14%/
14% vs 22%/22% for placebo, 3 mg , 6 mg , 12 mg two
times per day, 24 mg OD and 24 mg two times per day,
respectively).12 14 After 16 weeks of induction therapy,
patients were re-randomised to either UPA 3 mg, 12 mg
or 24 mg two times per day for maintenance therapy up
until week 52. A dose–response in clinical as well as endo-
scopic outcomes was shown over 36 weeks of treatment in
initial responders of the induction phase (clinical/endo-
scopic remission at week 52: 41.2%/25% vs 62.5%/25%
vs 73.3%/37.5% vs 40%/10% for UPA 3mg , 6mg , 12mg
two times per day and 24 OD).13 14 JAK-1 selective treat-
ment with FILGO 200 mg OD resulted in significantly
more patients achieving clinical remission (Crohn’s Dis-
ease Activity Index <150 at week 10: 47% vs 23% for
FILGO 200 mg OD vs placebo). Results on endoscopic
outcomes were numerically higher, although not statisti-
cally different at week 10 (50% response: 25% vs 14%,
remission: 14% vs 7% at week 10, for FILGO 200 mg OD
and placebo, respectively).82 Detailed results of trials
investigating JAKi and TNFi are shown in table 2.
Safety
All RCTs with a valid comparator (placebo or active treat-
ment arm in the respective time period) were assessed for
AEs of special interest (see online supplemental appen
dix tables S4.1.1–S4.1.8 for details of included reports).
Numerically higher rates of serious AEs, infections, ser-
ious infections and especially herpes zoster (HZ) were
identified when comparing JAKi treatment arms with
placebo arms (see online supplemental appendix tables
S4.2.1–S4.2.8 for detailed results). AEss of special interest
are shown in online supplemental appendix tables S4.3.
1–S4.3.8. Liver enzymes and creatine kinase elevations as
well as grade 3 or 4 lymphopenia/leucopenia appeared
more frequently during JAKi treatment.
Assessment of rare events, especially VTE (that is, deep
vein thrombosis and pulmonary embolism) remained
difficult to assess due to scarcity of data and a largely
diverse database on the amplitude of VTE risk related to
the underlying disease. One cohort study using claims
databases investigated the risk of venous thromboembo-
lism in biological and JAKi-naïve patients with RA
(n=50 865) receiving TOFA versus patients receiving
TNFi and found a numerically higher, however, statisti-
cally nonsignificant VTE risk (pooled propensity score-
adjusted HR: 1.33; 95% CI 0.78 to 2.24).83
In some RCTs, compared to placebo, numerically
higher rates of DVT/PE were seen in JAKi-treated
patients, suggesting an increased risk for venous throm-
boembolism. However, reports of head-to-head studies
did not reveal a clear signal regarding VTE risk when
comparing TNFi and JAKi treatment arms during the
controlled period (table 3). While the individual reports
did not allow to discern major differences between JAKi
and placebo or active treatment arms regarding VTEs and
PEs, the regulators have published important informa-
tion after the time point of this SLR. For completeness,
we refer to the Food and Drug Adminstration report
revealing more VTE/PE for BARI at 4 mg,84 and to the
EMA report on a still ongoing trial of TOFA versus anti-
TNFs in patients with RA with cardiovascular risk factors
where significantly more VTE/PE and deaths were seen
with TOFA 10 mg two times per day but numerically also
for TOFA 5mg.85 86These important information also led
to black box warnings in the package inserts of marketed
JAKi and more long-term data will be needed, as also
meanwhile partly published for some of the drugs.87–90
No safety signal could be identified regarding major
cardiac adverse events (MACE), malignancies excluding
non-melanoma skin cancer. Table 3 shows AEs of special
interest in trials comparing JAKi next to TNFi and pla-
cebo treatment.
Additionally, 12 reports on integrated safety analyses of
RCTs+long-term extension trials (LTEs) were included in
the analysis. TOFA RCTs (until March 2015) comprising
Autoimmunity
Kerschbaumer A, et al. RMD Open 2020;6:e001374. doi:10.1136/rmdopen-2020-001374 7









































106 24 1.9 0.9 0 0 0 0
TOFA 5 mg two
times per day
+MTX
204 5.9 1.5 0 0 0 0
TOFA 10 mg two
times per day
+MTX
201 5.0 2.0 3.0 0 0.5 0
ADA 40 mg EOW
+MTX
204 2.5 0 0 0 0 0.5
Fleischmann 2017
(ORAL Strategy)31
MTX-IR Low TOFA 5 mg two
times per day
+PLC
384 24 9 2 1 0 0.26 <1 1 0
TOFA 5 mg two
times per day
+MTX
376 7 3 2 1 0 0 0 0
ADA 40 mg EOW
+MTX
386 6 2 2 0 0.26 0 <1 1
Taylor 2017 (RA-
BEAM)32
MTX-IR Low PLC+MTX 488 24 5 1 <1 0 0* 0* <1 <1 0
BARI 4 mg+ MTX 487 5 1 1 0 0.2* 0.2* <1 0 <1
ADA 40 mg EOW
+MTX




MTX-IR Low PLC+MTX 651 26 2.9 0.8 0.5 0 0 0.2 0.3 0.5
UPA 15 mg OD
+MTX
651 3.7 1.8 0.8 0.2 0.2 0.2 0 0.5 0
ADA 40 mg EOW
+MTX




csDMARD-IR Low PLC±csDMARD 105 12 1 0 0 0 0 0 0 0
TOFA 5 mg two
times per day
±csDMARD
107 3 0 1 0 0 2 0 0
TOFA 10 mg two
times per day
±csDMARD
104 1 0 0 0 0 0 1 0
ADA 40 mg EOW
±csDMARD





















































19 406 patient-years (PY) of treatment exposure within
RA showed stable AEs over time (median exposure
3.4 years). Nasopharyngitis, upper respiratory tract infec-
tions and urinary tract infections were the most common
AEs. Most common serious infections were pneumonia,
HZ, urinary tract infections and cellulitis, with baseline
glucocorticoid usage, age and geographic region (Asia)
being significant risk factors. No increased incidence rate
for malignancies excluding non-melanoma skin cancer
(standardised incidence ratio: 1.0; 95% CI 0.8 to 1.1) was
observed. Twenty-two gastrointestinal perforations (inci-
dence ratio: 0.11, 95% CI 0.07 to 0.17) were reported, all
in patients with concomitant non-steroidal anti-
inflammatory drugs (NSAIDs) or glucocorticoid therapy
(NSAIDs + glucocorticoids: n=10; NSAIDs only: n=9; glu-
cocorticoids only: n=3); 13 patients had a history of diver-
ticulitis or diverticulosis and two a history of gastric
ulcers.91 Consistent results were also observed in patients
with UC and PsO who were treated with TOFA in RCTs
and LTEs.92 93 Safety analyses on HZ events in patients
with PsO and UC found patients treated with TOFA at
increased risk for HZ infection, with age, Asian origin and
previous biological use as risk factor as well as dose-
dependent higher risks in patients treated with TOFA
10 mg two times per day versus TOFA 5 mg two times
per day.94–96 Although higher levels of low-density lipo-
protein, high-density lipoprotein and total cholesterol
were observed during TOFA treatment, no signal regard-
ing a higher risk of MACE was found in RA, PsO and UC
trials.97–99
Integrated safety on BARI in RA with 6637 total PY of
exposure (median 2.1 years) showed a higher risk for
infections including HZ; VTE (including deep vein
thrombosis/pulmonary embolism) were reported with
BARI 4 mg OD but not for placebo (IR 0.5/100PY, 95%
CI 0.3 to 0.7) without differences between BARI 2 mg (IR
0.5/100PY) and BARI 4 mg (IR 0.6/100 PY). These were
associated with age, higher BMI, history of DVT/PE and
use of selective cyclooxygenase-2 inhibitors. Higher rates
of non-melanoma skin cancer were identified in BARI
4 mg OD compared to BARI 2 mg OD-treated patients.
Three cases of gastrointestinal perforations were
reported in patients taking MTX+NSAIDs, with two
patients taking glucocorticoids. Ten cases of tuberculosis
(in endemic areas) were observed in BARI-treated
patients. No increased risk of MACE or malignancies
was identified.100
Pregnancy is a contraindication for JAKi therapy, and
patients were required to use contraception during the
RCTs. Therefore, only very limited data (two retrospective
analyses) on pregnancy outcomes were available.101 102
Clowse et al investigated pregnancy outcomes of patients
treated with TOFA in RA (31maternal cases: TOFAmono-
therapy n=18, TOFA+MTX n=13; 3 paternal cases) and
PsO (16 maternal cases, 41 paternal cases). Similar fre-
quencies of healthy newborns (n=25), no fetal death,
seven spontaneous abortions, eight medical terminations
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stenosis) were reported until April 2014. These frequen-
cies were consistent with background risks in the general
population as well as in patients with RA or PsO, although
confounded through concomitant MTX therapy in some
patients withRA.101 Further analysis onpregnancies inUC,
RA, PsO and PsA RCTs (up to March 2017) reported
results in line with the previous report with pregnancy
AEs during TOFA treatment appearing similar to those
in the general population.102
DISCUSSION
We conducted this SLR to inform the task force on points
to consider for the treatment of IMIDs with JAKi with data
of all reports and conference abstracts published until
March 2019.
Efficacy of JAK inhibition has been shown for several
agents being either pan-JAKi (TOFA, PEF) as well as JAK-
selective (BARI, UPA, FILGO, DEC) compounds. With
TOFA being the first and therefore most extensively stu-
died agent, the JAKi approved to date demonstrating
good efficacy in various indications. FILGO recently
received a positive opinion by the European Medicines
Agency, recommending the granting of a marketing
authorisation for treatment of RA. However, none of the
available JAKi was approved for PsO until now, as efficacy
data were especially promising in higher doses, but these
were not approved due to regulatory safety concerns. The
JAKi approved up until the date of submission of this
manuscript (TOFA, BARI, UPA) appeared to demon-
strate a similar safety profile with an increased risk of
infections (particularly HZ) and a potential risk of VTE.
Although overall rare, VTE were observed in patients at
risk for thrombosis, subsequently leading to warnings
issued by the regulators. However, large registry data
and studies of at-risk patients with sufficiently large
cohort and comparator arms for safety analyses are still
lacking.
There are several limitations of this SLR: (1) only one
researcher (AK) conducted the title and abstract screen-
ing, data extraction and RoB analysis; (2) we only reported
data narratively due to the heterogeneity of data; (3) safety
analyses were completely based on RCTs and their LTEs,
limiting the interpretability due to selection bias of clinical
trial patient populations, which are only partly comparable
to the general population; (4) RoB is difficult to assess in
conference abstracts (and was therefore not assessed).
Possibly, data of conference abstracts of trials with poor
study design and/or inconsistent or incomplete results
may therefore never get published in peer-reviewed jour-
nals. However, in advance of the meeting, critical ques-
tions regarding the SLR could be discussed with members
of the task force with long-standing experience in clinical
trials of JAKi, including efficacy and safety analyses, and re-
checked in the literature when needed.
This SLR formed the basis for the formulation of the
points to consider for the treatment of IMIDs with JAKi
and for the definition of the levels of evidence and
strengths of recommendations of each item.103
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